Skip to main content

Van Plew Daniel P's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Nov 17, 2021

Accession no.
0001708138-21-000085
Filed
Nov 17, 2021
Trade date
Nov 15-16, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.45M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Van Plew Daniel PCIK 0001411984Officer (EVP & General Mgr, Industrial)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2021Common StockMOption exerciseAcquired+25,000$270.43+$6,760,75051,931Direct
Nov 15, 2021Common StockFTax withholdingDisposed−18,222$641.50−$11,689,41333,709Direct
Nov 16, 2021Common StockSSaleDisposed−528$652.20F1−$344,361.633,181Direct
Nov 16, 2021Common StockSSaleDisposed−840$653.41F2−$548,864.432,341Direct
Nov 16, 2021Common StockSSaleDisposed−1,260$654.33F3−$824,455.831,081Direct
Nov 16, 2021Common StockSSaleDisposed−350$655.03F4−$229,260.530,731Direct
Nov 16, 2021Common StockSSaleDisposed−200$657.18F5−$131,43630,531Direct
Nov 16, 2021Common StockSSaleDisposed−697$658.50F6−$458,974.529,834Direct
Nov 16, 2021Common StockSSaleDisposed−2,403$659.42F7−$1,584,586.2627,431Direct
Nov 16, 2021Common StockSSaleDisposed−500$660.51F8−$330,25526,931Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2021Common StockMOption exerciseDisposed−25,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents volume-weighted average price of sales of 528 shares of Company stock on November 16, 2021 at prices ranging from $652.01 to $652.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F2

Represents volume-weighted average price of sales of 840 shares of Company stock on November 16, 2021 at prices ranging from $653.03 to $653.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 1,260 shares of Company stock on November 16, 2021 at prices ranging from $654.03 to $654.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 350 shares of Company stock on November 16, 2021 at prices ranging from $655.01 to $655.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 200 shares of Company stock on November 16, 2021 at prices ranging from $657.09 to $657.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 697 shares of Company stock on November 16, 2021 at prices ranging from $658.03 to $658.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 2,403 shares of Company stock on November 16, 2021 at prices ranging from $659.01 to $659.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F8

Represents volume-weighted average price of sales of 500 shares of Company stock on November 16, 2021 at prices ranging from $660.33 to $660.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)